The authorisation covers a hospital medicine for the short-term treatment of acute deterioration in severe chronic heart failure in adults, in accordance with the approved Product Information (Summary of Product Characteristics, SmPC). The new authorisation adds to Farmak International’s portfolio of registered medicines in Spain and reflects the company’s ongoing regulatory activities. Since the beginning of 2026, Farmak International has expanded the number of medicines authorised in Spain. The company intends to build on this progress by advancing further regulatory projects and continuing to advance regulatory projects in the Spanish pharmaceutical market. About Farmak International Farmak International is a Swiss-based pharmaceutical company focused on international business development, partnerships, and market expansion across Europe, MEA, SEA, and LATAM. Its full-cycle pharmaceutical capabilities span R&D, production, regulatory support, and commercialization, with a portfolio covering key therapeutic areas including complex generics, anaesthesiology and intensive care medicines, and MRI & CT contrast media. Product availability, regulatory status, and commercialization rights vary by country and may be restricted by intellectual property rights or other legal requirements. Products are not offered for sale or supplied where such rights prohibit sale or would result in intellectual property rights infringement. Customers are responsible for verifying all relevant intellectual property rights (including patents and SPCs) and for ensuring compliance with local laws.
